Also found in: Medical.
ActRIIBActivin A Receptor, Type IIB
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Activin and MSTN bind directly to one of two isoforms of type II receptors: ActRIIA and ActRIIB (Donaldson et al., 1999; Lee and McPherron, 2001; Rebbapragada et al., 2003; del Re et al., 2004).
One approach to inhibiting the MSTN effect is by blocking its signaling, which is initiated by interaction with the ActRIIB receptor.
ActRIIB cDNAs were cloned from several fish species (Funkenstein et al., 2012 and references therein).
Orpi et al., "Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance," Journal of Cachexia, Sarcopenia and Muscle, vol.
Shire has licensed the activin receptor type TIB (ActRIIB) class of molecules being developed for the potential treatment of Duchenne Muscular Dystrophy (DMD), from Acceleron Pharma, Inc.
9 September 2010 - US biopharmaceutical company Acceleron Pharma Inc and Shire plc (LON: SHP) said Thursday they have inked a USD498m (EUR391.3m) joint development and commercialisation agreement for ACE-031 and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway.
Shire will receive an exclusive licence to Acceleron's ActRIIB molecules, including ACE-031, in markets outside of North America.
The poster describes PK/PD and other analysis of ACE-031, an Fc fusion of ActRIIB decoy receptor of myostatin in animal species and humans, and describes the positive impact the analysis has had in guiding further development.